If you have been reading about stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
== EMAIL invention controversy == Ayyadurai is notable for his widely disputed claim of being the "inventor of email". His claim is based on an electronic mail software called EMAIL, an implementation of interoffice email system, which he wrote as a 14-year-old student at Livingston High School, New Jersey, in 1979. Initial reports that repeated Ayyadurai's assertion—from organizations such as The Washington Post and the Smithsonian Institution—were followed by public retractions. These corrections were triggered by objections from historians and ARPANET pioneers who cited the fact the history of email dated back to the early 1970s. Ayyadurai started a campaign in 2011 in which he rebranded himself as the "Inventor of Email"; according to a paper published in Information & Culture, he "provoked a dramatic succession of exaggerated claims, credulous reporters, retractions, and accusations that a cabal of industry insiders and corrupt Wikipedia editors are colluding to hide the truth." A November 2011 Time Techland interview by Doug Aamoth, entitled "The Man Who Invented Email", argued that EMAIL represented the birth of email "as we currently know it". In that interview, Ayyadurai recalled that Les Michelson, the former particle scientist at Brookhaven National Labs who assigned Ayyadurai the project, had the idea of creating an electronic mail system that uses the header conventions of a hardcopy memorandum. Ayyadurai recalled Michelson as saying: "Your job is to convert that into an electronic format.
The chemical composition of the electronic cigarette aerosol varies across and within manufacturers. Limited data exists regarding their chemistry. However, researchers at Johns Hopkins University analyzed the vape clouds of popular brands such as Juul and Vuse, and found "nearly 2,000 chemicals, the vast majority of which are unidentified." The aerosol of e-cigarettes is generated when the e-liquid comes in contact with a coil heated to a temperature of roughly 100–250 °C (212–482 °F) within a chamber, which is thought to cause pyrolysis of the e-liquid and could also lead to decomposition of other liquid ingredients. The aerosol (mist) produced by an e-cigarette is commonly but inaccurately called vapor. E-cigarettes simulate the action of smoking, but without tobacco combustion. The e-cigarette aerosol looks like cigarette smoke to some extent. E-cigarettes do not produce aerosol between puffs. The e-cigarette aerosol usually contains propylene glycol, glycerin, nicotine, flavors, aroma transporters, and other substances. The levels of nicotine, tobacco-specific nitrosamines (TSNAs), aldehydes, metals, volatile organic compounds (VOCs), flavors, and tobacco alkaloids in e-cigarette aerosols vary greatly. The yield of chemicals found in the e-cigarette aerosol varies depending on, several factors, including the e-liquid contents, puffing rate, and the battery voltage. Metal parts of e-cigarettes in contact with the e-liquid can contaminate it with metals. Heavy metals and metal nanoparticles have been found in tiny amounts in the e-cigarette aerosol.
=== 1970: In the Wake of Poseidon and Lizard === King Crimson spent 1970 in a state of flux with various line-up changes, thwarted tour plans, and difficulties in finding a satisfactory musical direction, while Fripp was learning and developing as a songwriter during the writing process of the next three albums. As well as guitar, Fripp took on keyboard duties, while Sinfield expanded his creative role to operating synthesizers. Following McDonald's and Giles's departure, Lake, unsure of the band's future without them, began discussions with Keith Emerson of the Nice about possibly forming a new band together. With Fripp and Sinfield planning the recording of the second King Crimson album, and Lake's position uncertain, the band's management booked Elton John to sing on the album, a decision cancelled by Fripp after he listened to John's then-only album, Empty Sky, and deemed his singing style to be not right for King Crimson. Lake agreed to stay with the band until Emerson had completed remaining commitments with the Nice, at which point he left to form Emerson, Lake & Palmer with Emerson and Carl Palmer of Atomic Rooster. On the resulting In the Wake of Poseidon album, Lake provided all the lead vocals except on "Cadence and Cascade", which featured Fripp's old school friend Gordon Haskell. The sessions also included Michael and Peter Giles on drums and bass respectively, saxophonist Mel Collins (formerly of the band Circus), and jazz pianist Keith Tippett. Upon its release in May 1970, In the Wake of Poseidon reached No. 4 in the UK and No. 31 in the US.
The first record of tea in English came from a letter written by Richard Wickham, who ran an East India Company office in Japan, writing to a merchant in Macao requesting "the best sort of chaw" in 1615. Peter Mundy, a traveller and merchant who came across tea in Fujian in 1637, wrote, "chaa – only water with a kind of herb boyled in it". Tea was sold in a coffee house in London in 1657, Samuel Pepys tasted tea in 1660, and Catherine of Braganza took the tea-drinking habit to the English court when she married Charles II in 1662. Tea, however, was not widely consumed in the British Isles until the 18th century and remained expensive until the latter part of that period. English drinkers preferred to add sugar and milk to black tea, as the tea of choice in the 1720s. Tea smuggling during the 18th century led to the general public being able to afford and consume tea. The British government removed the tax on tea, thereby eliminating the smuggling trade, by 1785. In Britain and Ireland, tea was initially consumed as a luxury item on special occasions, such as religious festivals, wakes, and domestic work gatherings. The price of tea in Europe fell steadily during the 19th century, especially after Indian tea began to arrive in large quantities; by the late 19th century tea had become an everyday beverage for all levels of society. Consuming tea played a role in historical events – the Tea Act of 1773 provoked the Boston Tea Party that escalated into the American Revolution.
Virginia Minnich (1910–1996) was an American molecular biologist and hematology researcher known for discovering hemoglobin E, an abnormal form of hemoglobin that can cause blood disorders, and for working out the glutathione synthesis pathway. She was a noted blood morphologist and teacher and helped set up hematology laboratories around the world. She was the first person without a PhD or MD to be appointed a Professor of Medicine at Washington University School of Medicine.
Sources: en.wikipedia.org
Mescaline given orally appears to be subject to first-pass metabolism of about 50%. Following the first pass, mescaline appears to be subject to relatively limited metabolism. The primary metabolic pathway of mescaline is oxidative deamination. The specific enzymes mediating the deamination of mescaline are controversial however. Monoamine oxidase (MAO), diamine oxidase (DAO; histamine oxidase), semicarbazide-sensitive amine oxidase (SSAO), and/or other enzymes may be responsible. Preclinical studies of mescaline given in combination with inhibitors of MAO and/or DAO, such as iproniazid, pargyline, and semicarbazide, have been conducted, but findings have been conflicting. Mescaline has been reported to be a poor or negligible substrate of highly purified human MAO in-vitro. Mescaline is converted via deamination into 3,4,5-trimethoxyphenylacetaldehyde (TMPA) as an intermediate and then into 3,4,5-trimethoxyphenylacetic acid (TMPAA) or 3,4,5-trimethoxyphenylethanol (TMPE). β-Hydroxymescaline may also be a minor metabolite of mescaline formed by dopamine β-hydroxylase (DBH), though this remains unclear. Mescaline appears not to be subject to metabolism by CYP2D6 based on in-vitro studies with human liver microsomes. Similarly, the in-vitro cytotoxicity of mescaline does not appear to be affected by cytochrome P450 (CYP450) enzyme inhibitors. Conversely, it was potentiated by the MAO-A inhibitor clorgiline but not by the MAO-B inhibitor rasagiline.
== Early life and education == Fred McLafferty was born in Evanston, Illinois in 1923, but attended grade school in Omaha, Nebraska, graduating from Omaha North High School in 1940. The urgent requirements of World War II accelerated his undergraduate studies at the University of Nebraska; he obtained his B.S. degree in 1943 and thereafter entered the US armed forces. He served in western Europe during the invasion of Germany and was awarded the Combat Infantryman Badge, a Purple Heart, five Bronze Star Medals and a Presidential Unit Citation. He returned to the University of Nebraska in late 1945 and completed his M.S. degree in 1947. He went on to work under William Miller at Cornell University where he earned his Ph.D. in 1950. He went on to a postdoctoral researcher position at the University of Iowa with R.L. Shriner.
. However, away from this reference point, errors will accumulate over time thus convergence test is needed to find an optimal time step for more accurate results. Among these three reproduction numbers,
Collagen alpha-1(XV) chain is a protein that in humans is encoded by the COL15A1 gene. This gene encodes the alpha chain of type XV collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Type XV collagen has a wide tissue distribution but the strongest expression is localized to basement membrane zones so it may function to adhere basement membranes to underlying connective tissue stroma. Mouse studies have shown that collagen XV deficiency is associated with muscle and microvessel deterioration. Type XV collagen is known to be a tumor suppressor that can be used to understand tumor cells environment. Type XV collagen provides the membrane with support and cell anchorage but does not typically have a tight structural network. Changes of collagen XV can be known to lead to cancer-like behavior in tissues. The loss of collagen XV would no longer provide structural support for the membrane, which can cause tumor cells to invade the basement membrane; prompting possible metastasis. The over expression of collagen XV is known to be found in cervical cancer. For possible future medical purposes the lack of collagen XV present in tissues can be a means for indication of an invasive tumor.
Ginkgos have a conical crown in youth which becomes progressively broader and more irregular with age. They are large trees, normally reaching a height of 20–35 m (66–115 ft), with some specimens in China being over 40 m (130 ft). The tree has an angular crown and long, somewhat erratic branches, and is usually deep-rooted and resistant to wind and snow damage. Young trees are often tall and slender, and sparsely branched; the crown becomes broader as the tree ages. A combination of resistance to disease, insect-resistant wood, and the ability to form aerial roots and sprouts makes ginkgos durable, with some specimens estimated to be more than 3,500 years old.
Sources: en.wikipedia.org
In contrast, it declined by approximately 2.2 percent in the placebo group (P=0.006). There is an emerging recognition of the role that diet and exercise can play in functionally limiting symptom progression. This is an area for further study, as there is no clear consensus guideline, but rather a body of case study work that suggests that appropriate physical activity can be an effective tool in managing disease progression. In one such study, side-alternating vibration training was used 3 times weekly for 15 weeks. The results showed that, at 15 weeks, the patient had a 116-meter (70%) improvement to their 6MWT, which is significant compared with the results from the aforementioned LOTS study.
After these events, in 1989 Assembly of Socialist Republic of Serbia voted for constitution amendments that revoked high autonomy for provinces of Vojvodina and Kosovo. After Slovenian authorities forbid a group of Serbs supporting his politics to gather in Ljubljana, Milosević started a trade war with Socialist Republic of Slovenia in late 1989. This Serbian–Slovenian conflict culminated in January 1990 on 14th Congress of the League of Communists of Yugoslavia when Slovenians left the meeting followed by Croatian delegates. After 1990, the state was known simply as Republic of Serbia (Serbo-Croatian: Република Србија / Republika Srbija), and in December of the same year, Slobodan Milošević was elected as first President of the Republic. In 1992, when the Federal Republic of Yugoslavia was formed, Serbia became one of its two constituent republics. In 2003, this state union was re-formed into Serbia and Montenegro, and in 2006, Serbia became an independent republic after Montenegro separated.
Kenneth D. Tew is a Scottish-American pharmacologist, academic and author. He is a professor in the Department of Cell & Molecular Pharmacology and the John C. West Endowed Chair in Cancer Research at the Medical University of South Carolina. Tew's research primarily focuses on identifying cancer strategies with strong translational potential, particularly in the context of redox pathways, and resistance to various drugs to understand redox mechanisms and their connections to essential signaling pathways. He has authored, co-authored and edited research articles and books such as Preclinical and Clinical Modulation of Anticancer Drugs and Basic Science of Cancer. He is the recipient of the Outstanding Investigator Grant from the National Cancer Institute in 1993, the 2003 American Cancer Society Scientific Research Award and the 2010 Astellas USA Foundation Award from the American Society for Pharmacology and Experimental Therapeutics. Tew is an Elected Fellow of the American Association for the Advancement of Science and the American Society for Pharmacology and Experimental Therapeutics. He is an Executive Editor of Biomedicine & Pharmacotherapy.
== Occurrence == The hydroxy group is pervasive in chemistry and biochemistry. Many inorganic compounds contain hydroxyl groups, including sulfuric acid, the chemical compound produced on the largest scale industrially. Hydroxy groups participate in the dehydration reactions that link simple biological molecules into long chains. The joining of a fatty acid to glycerol to form a triacylglycerol removes the −OH from the carboxy end of the fatty acid. The joining of two aldehyde sugars to form a disaccharide removes the −OH from the carboxy group at the aldehyde end of one sugar. The creation of a peptide bond to link two amino acids to make a protein removes the −OH from the carboxy group of one amino acid.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.